The company has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. It has also established a fully integrated R&D platform with world-class discovery and development capabilities.
Hutchmed has a GMP standard manufacturing facility in Suzhou, China, which produces clinical and commercial supplies of its oncology assets. A new large scale manufacturing facility is being constructed in Shanghai, China.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze